- Home
- SYNA vs SRPT Comparison
SYNA vs SRPT Comparison
Compare SYNA & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYNA | SRPT |
|---|---|---|
| Founded | 1986 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2001 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SYNA | SRPT |
|---|---|---|
| Price | $137.24 | $17.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 29 |
| Target Price | ★ $100.78 | $25.85 |
| AVG Volume (30 Days) | 1.0M | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | $663,588,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $12.63 | N/A |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | ★ 21.04 | 15.58 |
| 52 Week Low | $58.06 | $10.42 |
| 52 Week High | $149.11 | $43.92 |
Technical Indicators
Market Signals| Indicator | SYNA | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.01 | 42.49 |
| Support Level | $65.25 | $17.11 |
| Resistance Level | N/A | $18.10 |
| Average True Range (ATR) | 8.97 | 0.77 |
| MACD | 0.60 | -0.09 |
| Stochastic Oscillator | 73.68 | 28.85 |
Price Performance
Historical ComparisonAbout SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.